Anna Tarren
A5089299353- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- vaccines and immunoinformatics approaches
- Bacteriophages and microbial interactions
- Immune cells in cancer
- Immunotherapy and Immune Responses
- Peptidase Inhibition and Analysis
- Plant Virus Research Studies
- Polyomavirus and related diseases
- Cancer Genomics and Diagnostics
- Immune Cell Function and Interaction
- Renal cell carcinoma treatment
Dana-Farber Cancer Institute
2021-2025
Personalized cancer vaccines (PCVs) can generate circulating immune responses against predicted neoantigens1–6. However, whether such target driver mutations, lead to recognition of a patient's tumour and result in clinical activity are largely unknown. These questions particular interest for patients who have tumours with low mutational burden. Here we conducted phase I trial (ClinicalTrials.gov identifier NCT02950766) test neoantigen-targeting PCV high-risk, fully resected clear cell renal...
MS is the most effective method to directly identify peptides presented on human leukocyte antigen (HLA) molecules. However, current standard approaches often use 500 million or more cells as input achieve high coverage of immunopeptidome, and therefore, these methods are not compatible with limited amounts tissue available from clinical tumor samples. Here, we evaluated microscaled basic reversed-phase fractionation separate HLA peptide samples offline followed by ion mobility coupled...
Although local tissue-based immune responses are critical for elucidating direct tumor-immune cell interactions, peripheral increasingly recognized as occupying an important role in anticancer immunity. We evaluated serial blood samples from patients with advanced epithelial ovarian cancer (EOC) undergoing standard-of-care neoadjuvant carboplatin and paclitaxel chemotherapy (including dexamethasone prophylaxis of paclitaxel-associated hypersensitivity reactions) to characterize the evolution...
Cancers avoid immune surveillance through an array of mechanisms, including perturbation HLA class I antigen presentation. Merkel cell carcinoma (MCC) is aggressive, HLA-I-low, neuroendocrine the skin often caused by polyomavirus (MCPyV). Through characterization 11 newly generated MCC patient-derived lines, we identified transcriptional suppression several presentation genes. To systematically identify regulators HLA-I loss in MCC, performed parallel, genome-scale, gain- and...
Abstract Mass spectrometry is the most effective method to directly identify peptides presented on HLA molecules. However, current standard approaches often require many millions of cells for input material achieve high coverage immunopeptidome and are therefore not compatible with limited amounts tissue available from clinical tumor samples. Here, we evaluated microscaled basic reversed-phase fractionation separate peptide samples off-line followed by ion mobility coupled LC-MS/MS analysis....